| Year |
Citation |
Score |
| 2024 |
Mai N, Dos Anjos CH, Razavi P, Safonov A, Patil S, Chen Y, Drago JZ, Modi S, Bromberg JF, Dang CT, Liu D, Norton L, Robson M, Chandarlapaty S, Jhaveri K. Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer. Npj Breast Cancer. 10: 92. PMID 39424631 DOI: 10.1038/s41523-024-00699-3 |
0.305 |
|
| 2024 |
Jhaveri K, Mai N, Dos Anjos CH, Razavi P, Safonov A, Patil S, Chen Y, Drago J, Modi S, Bromberg J, Dang C, Liu D, Norton L, Robson M, Chandarlapaty S. Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer. Research Square. PMID 38746324 DOI: 10.21203/rs.3.rs-4237867/v1 |
0.305 |
|
| 2023 |
LeVee A, Spector K, Larkin B, Dezem F, Plummer J, Dadmanesh F, Patil S, McArthur HL. Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+ breast cancer. Cancer Medicine. PMID 36971049 DOI: 10.1002/cam4.5817 |
0.333 |
|
| 2023 |
Crown A, McCartan D, Curry MA, Patil S, Kamer S, Goldfarb S, Gemignani ML. Pregnancy-associated breast cancer: does timing of presentation affect outcome? Breast Cancer Research and Treatment. PMID 36662395 DOI: 10.1007/s10549-022-06833-8 |
0.304 |
|
| 2022 |
Page DB, Beal K, Linch SN, Spinelli KJ, Rodine M, Halpenny D, Modi S, Patil S, Young RJ, Kaley T, Merghoub T, Redmond D, Wong P, Barker CA, Diab A, et al. Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer. 8: 50. PMID 35440655 DOI: 10.1038/s41523-022-00404-2 |
0.33 |
|
| 2022 |
Ferraro E, Singh J, Patil S, Razavi P, Modi S, Chandarlapaty S, Barrio AV, Malani R, Mellinghoff IK, Boire A, Wen HY, Brogi E, Seidman AD, Norton L, Robson ME, et al. Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer. 8: 37. PMID 35319017 DOI: 10.1038/s41523-022-00380-7 |
0.323 |
|
| 2021 |
Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier MN, Sklarin NT, Chandarlapaty S, Modi S. A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with -mutated HER2-positive metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33947692 DOI: 10.1158/1078-0432.CCR-21-0047 |
0.313 |
|
| 2021 |
Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. The Cochrane Database of Systematic Reviews. 4: CD011395. PMID 33886122 DOI: 10.1002/14651858.CD011395.pub2 |
0.339 |
|
| 2020 |
Copeland-Halperin RS, Al-Sadawi M, Patil S, Liu JE, Steingart RM, Dang CT, Yu AF. Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer. Jama Oncology. PMID 33057570 DOI: 10.1001/jamaoncol.2020.4749 |
0.333 |
|
| 2020 |
Ged Y, Gupta R, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Voss MH, Feldman DR, Akin O, Patil S, Motzer RJ, Rini BI, Lee CH. Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. Bmc Urology. 20: 84. PMID 32616076 DOI: 10.1186/S12894-020-00647-W |
0.303 |
|
| 2020 |
Quezada-Diaz FF, Smith JJ, Jimenez-Rodriguez RM, Wasserman I, Pappou EP, Patil S, Wei IH, Nash GM, Guillem JG, Weiser MR, Paty PB, Garcia-Aguilar J. Patient-Reported Bowel Function in Patients with Rectal Cancer Managed by a Watch-and-Wait Strategy after Neoadjuvant Therapy: A Case-Control Study. Diseases of the Colon and Rectum. PMID 32217857 DOI: 10.1097/Dcr.0000000000001646 |
0.371 |
|
| 2020 |
McHugh DJ, Funt SA, Silber D, Knezevic A, Patil S, O'Donnell D, Tsai S, Reuter VE, Sheinfeld J, Carver BS, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902712. PMID 32109195 DOI: 10.1200/Jco.19.02712 |
0.36 |
|
| 2020 |
Feldman DR, Knezevic A, Wilson K, Bromberg M, Budnick A, McHugh DJ, Larsen E, Bajorin DF, Motzer RJ, Tonorezos ES, Patil S, Funt SA. Detailed evaluation of hearing loss (HL) associated with high-dose (HD) carboplatin for salvage treatment of germ cell tumors (GCT). Journal of Clinical Oncology. 38: 401-401. DOI: 10.1200/Jco.2020.38.6_Suppl.401 |
0.303 |
|
| 2020 |
Goldfarb SB, Saban S, Arkema A, Patil S, Flynn J, Goldfrank DJ, Norton L, Carter J. Objective and subjective vulvovaginal symptoms in breast cancer patients. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E24056 |
0.383 |
|
| 2020 |
Ferraro E, Barrio AV, Patil S, Robson ME, Dang CT. Incidence of brain metastases in patients receiving neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in HER2-positive early breast cancer (BC). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E12653 |
0.41 |
|
| 2020 |
Garcia-Aguilar J, Patil S, Kim JK, Yuval JB, Thompson H, Verheij F, Lee M, Saltz LB. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. Journal of Clinical Oncology. 38: 4008-4008. DOI: 10.1200/Jco.2020.38.15_Suppl.4008 |
0.342 |
|
| 2020 |
Gucalp A, Boyle LA, Alano T, Arumov A, Gounder MM, Patil S, Feigin K, Edelweiss M, D'Andrea G, Bromberg J, Goldfarb SB, Ligresti L, Wong ST, Traina TA. Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer. Journal of Clinical Oncology. 38: 1017-1017. DOI: 10.1200/Jco.2020.38.15_Suppl.1017 |
0.385 |
|
| 2020 |
Blinder VS, Patil S, Eberle C, Jung G, Kampel LJ, Hwang C, Bao T, Robson ME, Malik M, Gany F. Abstract PR03: Disparities in work status after treatment for breast cancer: A controlled, longitudinal study Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-Pr03 |
0.41 |
|
| 2020 |
Traina TA, Jones LW, Blinder V, Scott J, Boyle LA, Arumov A, Alano T, Patil S, DeFusco P, Lamparella N, Robson M, Gucalp A. Abstract P5-12-09: Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-12-09 |
0.429 |
|
| 2020 |
Singh JC, Patil S, Norton L, Robson M, Dang C. Abstract P2-16-10: Disease free survival rate with dose dense Doxorubicin and Cyclophosphamide followed by weekly Paclitaxel with Trastuzumab and Pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-16-10 |
0.475 |
|
| 2020 |
Copeland-Halperin R, Al-Sadawi M, Patil S, Yadav N, Liu JE, Dang C, Steingart R, Yu AF. The Impact Of Cardiotoxicity And Trastuzumab Interruption On Breast Cancer Outcomes Journal of the American College of Cardiology. 75: 741. DOI: 10.1016/S0735-1097(20)31368-1 |
0.422 |
|
| 2019 |
Iyengar NM, Smyth LM, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Patil S, Ulaner GA, Jochelson M, et al. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. Jama Network Open. 2: e1916211. PMID 31774522 DOI: 10.1001/jamanetworkopen.2019.16211 |
0.34 |
|
| 2019 |
Ganesh K, Wu C, O'Rourke KP, Szeglin BC, Zheng Y, Sauvé CG, Adileh M, Wasserman I, Marco MR, Kim AS, Shady M, Sanchez-Vega F, Karthaus WR, Won HH, Choi SH, ... ... Patil S, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine. PMID 31591597 DOI: 10.1038/S41591-019-0584-2 |
0.38 |
|
| 2019 |
Zhi WI, Chen P, Kwon A, Chen C, Harte SE, Piulson L, Li S, Patil S, Mao JJ, Bao T. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing. Breast Cancer Research and Treatment. PMID 31456070 DOI: 10.1007/S10549-019-05416-4 |
0.406 |
|
| 2019 |
Funt SA, Patil S, Feldman DR, Motzer RJ, Bajorin DF, Sheinfeld J, Tickoo SK, Reuter VE, Bosl GJ. Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801608. PMID 31233353 DOI: 10.1200/Jco.18.01608 |
0.341 |
|
| 2019 |
Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Voss MH, Motzer RJ. Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clinical Genitourinary Cancer. PMID 31151928 DOI: 10.1016/J.Clgc.2019.04.006 |
0.326 |
|
| 2019 |
Krystel-Whittemore M, Xu J, Brogi E, Ventura K, Patil S, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Research and Treatment. PMID 31144151 DOI: 10.1007/S10549-019-05295-9 |
0.464 |
|
| 2019 |
Morikawa A, de Stanchina E, Pentsova E, Kemeny MM, Li BT, Tang K, Patil S, Fleisher M, Van Poznak C, Norton L, Seidman AD. Phase I study of intermittent high dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30988080 DOI: 10.1158/1078-0432.Ccr-18-3502 |
0.419 |
|
| 2019 |
Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, Chisanga D, Shi W, Collins I, Baron-Hay S, Patil S, Lindeman G, Khasraw M. Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response. Plos One. 14: e0210891. PMID 30763338 DOI: 10.1371/Journal.Pone.0210891 |
0.438 |
|
| 2019 |
Chow OS, Patil S, Keskin M, Smith JJ, Widmar M, Smith DD, Avila K, Shia J, Chu P, Garcia-Aguilar J. Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 30719677 DOI: 10.1007/S11605-019-04119-X |
0.338 |
|
| 2019 |
Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. The Oncologist. PMID 30602614 DOI: 10.1634/Theoncologist.2018-0512 |
0.443 |
|
| 2019 |
Jimenez-Rodriguez RM, Quezada-Diaz FF, Hameed I, Patil S, Smith JJ, Garcia-Aguilar J. Organ preservation in rectal cancer patients treated with total neoadjuvant therapy. Journal of Clinical Oncology. 37: 692-692. DOI: 10.1200/Jco.2019.37.4_Suppl.692 |
0.379 |
|
| 2019 |
Oza S, Blinder VS, Tran C, Patil S, Gany F, Roberts N, Kampel LJ, Malik M, Bao T. Exercise trends among previously non-exercising breast cancer survivors: Analysis of an ethnically diverse sample. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E23048 |
0.326 |
|
| 2019 |
Ged Y, Lee C, Sanchez A, Duzgol C, Chaim J, Carlo MI, Foster A, Akin O, Feldman DR, Hakimi AA, Patil S, Motzer RJ, Furberg H, Voss MH. Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16103 |
0.317 |
|
| 2019 |
Comen EA, Bryce Y, Page DB, Solomon SB, Rodine M, Abaya CD, Morris EA, Plitas G, El-Tamer M, Gemignani M, Sclafani LM, Morrow M, Brogi E, Patil S, Ho T, et al. Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC). Journal of Clinical Oncology. 37: 592-592. DOI: 10.1200/Jco.2019.37.15_Suppl.592 |
0.392 |
|
| 2019 |
Traina TA, Boyle LA, Arumov A, Patil S, Edelweiss M, DeFusco PA, Gorsky M, Lamparella NE, Modi S, Sanford RA, Gucalp A. Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC. Journal of Clinical Oncology. 37: 546-546. DOI: 10.1200/Jco.2019.37.15_Suppl.546 |
0.31 |
|
| 2019 |
Feldman DR, Hu JS, Patil S, Reuter VE, Srinivas S, Stadler WM, Costello BA, Milowsky MI, Appleman LJ, Dorff TB, Bromberg M, Joseph G, Funt SA, Bajorin DF, Bosl GJ, et al. Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). Journal of Clinical Oncology. 37: 4563-4563. DOI: 10.1200/Jco.2019.37.15_Suppl.4563 |
0.349 |
|
| 2019 |
Lacouture M, Phillips G, Freites-Martinez A, Patil S, Samuels A, Shapiro J, Kukoyi O, Goldfarb S. Abstract P4-16-07: The CHANCE study: Mechanical skin changes among women with non-metastatic breast cancer receiving chemotherapy and endocrine therapy Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-16-07 |
0.419 |
|
| 2018 |
Quezada-Diaz F, Jimenez-Rodriguez RM, Pappou EP, Joshua Smith J, Patil S, Wei I, Guillem JG, Paty PB, Nash GM, Weiser MR, Garcia-Aguilar J. Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 30350191 DOI: 10.1007/S11605-018-4003-7 |
0.39 |
|
| 2018 |
Marco MR, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, Cataldo PA, Hunt SR, Kumar A, Herzig DO, Fichera A, Polite BN, Hyman NH, Ternent CA, Stamos MJ, et al. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Diseases of the Colon and Rectum. 61: 1146-1155. PMID 30192323 DOI: 10.1097/Dcr.0000000000001207 |
0.39 |
|
| 2018 |
Green AK, Aviki EM, Matsoukas K, Patil S, Korenstein D, Blinder V. Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. PMID 30094552 DOI: 10.1007/S10549-018-4909-5 |
0.419 |
|
| 2018 |
Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, et al. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. Jama Oncology. PMID 29978187 DOI: 10.1001/Jamaoncol.2018.1986 |
0.355 |
|
| 2018 |
Morris PG, Rota S, Cadoo K, Zamora S, Patil S, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Norton L, Hudis CA, et al. Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical Breast Cancer. PMID 29680193 DOI: 10.1016/J.Clbc.2018.03.010 |
0.331 |
|
| 2018 |
Muhsen S, Moo TA, Patil S, Stempel M, Powell S, Morrow M, El-Tamer M. Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. Annals of Surgical Oncology. PMID 29564588 DOI: 10.1245/S10434-018-6422-9 |
0.408 |
|
| 2018 |
Ged Y, Knezevic A, Chen Y, Redzematovic A, Carlo MI, Lee C, Feldman DR, Patil S, Motzer RJ, Voss MH. Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF). Journal of Clinical Oncology. 36: 678-678. DOI: 10.1200/Jco.2018.36.6_Suppl.678 |
0.354 |
|
| 2018 |
Feldman DR, Lee C, Molina AM, Knezevic A, Chen Y, Chaim J, Coskey DT, Ged Y, Tickoo S, Reuter VE, Patil S, Xiao H, Aghalar J, Apollo AJ, Carlo MI, et al. Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial. Journal of Clinical Oncology. 36: 627-627. DOI: 10.1200/Jco.2018.36.6_Suppl.627 |
0.33 |
|
| 2018 |
Green AK, Aviki E, Patil S, Blinder VS. Effect of race on completion of chemotherapy in early stage breast cancer: A systematic review and meta-analysis. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E18749 |
0.439 |
|
| 2018 |
Morikawa A, Pentsova E, Kemeny M, Patil S, Li BT, Tang K, Fleisher M, Poznak CHV, Norton L, Seidman AD. Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer with central nervous system metastases. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E14016 |
0.397 |
|
| 2018 |
Wang R, Smyth LM, Iyengar NM, Modi S, Chandarlapaty S, Patil S, Norton L, Baselga J, Hudis CA, Dang CT. Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E13005 |
0.439 |
|
| 2018 |
Lacouture ME, Freites-Martinez A, Patil S, Samuels A, Shapiro J, Ciccolini K, Kukoyi O, Goldfarb SB. The CHANCE study: A prospective, longitudinal study of chemotherapy and hormonal therapy induced hair changes and alopecia, skin aging and nail changes in women with non-metastatic breast cancer. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E12500 |
0.466 |
|
| 2018 |
Blinder VS, Patil S, Eberle CE, Jung G, Kampel LJ, Hwang C, Bao T, Robson ME, Malik M, Gany F. Work status after treatment for breast cancer: A controlled, prospective, longitudinal study of an ethnically diverse cohort. Journal of Clinical Oncology. 36: 6583-6583. DOI: 10.1200/Jco.2018.36.15_Suppl.6583 |
0.381 |
|
| 2018 |
Lyons T, Gucalp A, Arumov A, Patil S, Edelweiss M, Gorsky M, Troso-Sandoval TA, Bromberg J, Sanford RA, Iyengar NM, Modi S, Gupta R, Traina TA. Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer. Journal of Clinical Oncology. 36: 531-531. DOI: 10.1200/Jco.2018.36.15_Suppl.531 |
0.421 |
|
| 2018 |
Ged Y, Knezevic A, Chen Y, Redzematovic A, Carlo MI, Lee C, Feldman DR, Patil S, Motzer RJ, Voss MH. Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant. Journal of Clinical Oncology. 36: 4577-4577. DOI: 10.1200/Jco.2018.36.15_Suppl.4577 |
0.323 |
|
| 2018 |
McHugh DJ, Funt S, Silber D, Knezevic A, Patil S, O'Donnell D, Tsai S, Reuter VE, Sheinfeld J, Carver BS, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR. Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT). Journal of Clinical Oncology. 36: 567-567. DOI: 10.1200/Jco.2018.36.15_Suppl.4552 |
0.366 |
|
| 2018 |
Funt S, McHugh DJ, Tsai S, O'Donnell D, Knezevic A, Patil S, Silber D, Reuter VE, Sheinfeld J, Carver BS, Carousso M, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR. Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts). Journal of Clinical Oncology. 36: 4550-4550. DOI: 10.1200/Jco.2018.36.15_Suppl.4550 |
0.356 |
|
| 2018 |
Feldman DR, Hu J, Srinivas S, Stadler WM, Costello BA, Appleman LJ, Milowsky MI, Patil S, Bromberg M, Nolan P, Dorff TB, Reuter VE, Al-Ahmadie H, Funt S, Bajorin DF, et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). Journal of Clinical Oncology. 36: 4508-4508. DOI: 10.1200/Jco.2018.36.15_Suppl.4508 |
0.35 |
|
| 2018 |
Tio M, Patil S, Traina TA, Robson ME, Khasraw M. Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis. Journal of Clinical Oncology. 36: 1076-1076. DOI: 10.1200/Jco.2018.36.15_Suppl.1076 |
0.389 |
|
| 2017 |
Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. Clinical Breast Cancer. PMID 29337140 DOI: 10.1016/J.Clbc.2017.12.009 |
0.439 |
|
| 2017 |
Page DB, Wen H, Brogi E, Dure D, Ross D, Spinelli KJ, Patil S, Norton L, Hudis C, McArthur HL. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact. Breast Cancer Research and Treatment. PMID 28986743 DOI: 10.1007/S10549-017-4520-1 |
0.428 |
|
| 2017 |
Shurell E, Olcese C, Patil S, McCormick B, Van Zee KJ, Pilewskie ML. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Cancer. PMID 28960259 DOI: 10.1002/Cncr.30972 |
0.404 |
|
| 2017 |
Muhsen S, Barrio AV, Miller M, Olcese C, Patil S, Morrow M, Van Zee KJ. Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Annals of Surgical Oncology. PMID 28828599 DOI: 10.1245/S10434-017-6043-8 |
0.302 |
|
| 2017 |
Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? Annals of Surgical Oncology. PMID 28766208 DOI: 10.1245/S10434-017-5931-2 |
0.446 |
|
| 2017 |
Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, et al. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research : Bcr. 19: 89. PMID 28764748 DOI: 10.1186/S13058-017-0879-5 |
0.443 |
|
| 2017 |
Mamtani A, Patil S, Stempel M, Morrow M. Erratum to: Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. Annals of Surgical Oncology. PMID 28718032 DOI: 10.1245/s10434-017-6004-2 |
0.327 |
|
| 2017 |
Morrow M, Van Zee KJ, Patil S, Petruolo O, Mamtani A, Barrio AV, Capko D, El-Tamer M, Gemignani ML, Heerdt AS, Kirstein L, Pilewskie M, Plitas G, Sacchini VS, Sclafani LM, et al. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients. Annals of Surgery. PMID 28650355 DOI: 10.1097/Sla.0000000000002354 |
0.433 |
|
| 2017 |
Mariotti V, Page DB, Davydov O, Hans D, Hudis CA, Patil S, Kunte S, Girotra M, Farooki A, Fornier MN. Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. Journal of Bone Oncology. 7: 32-37. PMID 28626628 DOI: 10.1016/J.Jbo.2016.10.004 |
0.311 |
|
| 2017 |
Glare PA, Nikolova T, Alickaj A, Patil S, Blinder V. Work Experiences of Patients Receiving Palliative Care at a Comprehensive Cancer Center: Exploratory Analysis. Journal of Palliative Medicine. PMID 28562160 DOI: 10.1089/Jpm.2016.0478 |
0.319 |
|
| 2017 |
Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, Morrow M. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology. PMID 28560596 DOI: 10.1245/S10434-017-5898-Z |
0.408 |
|
| 2017 |
Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, Coskey D, Nanjangud GJ, Voss MH, Feldman DR, Hsieh JJ, Hakimi AA, Chen YB, Motzer RJ, Lee CH. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clinical Genitourinary Cancer. PMID 28558987 DOI: 10.1016/J.Clgc.2017.04.012 |
0.322 |
|
| 2017 |
Mamtani A, Patil S, Stempel M, Morrow M. Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. Annals of Surgical Oncology. PMID 28429197 DOI: 10.1245/S10434-017-5866-7 |
0.457 |
|
| 2017 |
Mamtani A, Patil S, Stempel MM, Morrow M. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence? Cancer. PMID 28334423 DOI: 10.1002/Cncr.30658 |
0.453 |
|
| 2017 |
Smith JJ, Wasserman I, Milgrom SA, Chow OS, Chen CT, Patil S, Goodman KA, Garcia-Aguilar J. Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. International Journal of Radiation Oncology, Biology, Physics. 97: 924-930. PMID 28333014 DOI: 10.1016/J.Ijrobp.2016.12.015 |
0.316 |
|
| 2017 |
Blinder V, Eberle C, Patil S, Gany FM, Bradley CJ. Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. Health Affairs (Project Hope). 36: 274-281. PMID 28167716 DOI: 10.1377/Hlthaff.2016.1196 |
0.365 |
|
| 2017 |
Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D, Smyth LM, Modi S, Schweber S, Boafo C, Patil S, Norton L, Baselga J, et al. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. The Oncologist. PMID 28167568 DOI: 10.1634/Theoncologist.2016-0268 |
0.439 |
|
| 2017 |
Feliciano Y, Mamtani A, Morrow M, Stempel MM, Patil S, Jochelson MS. Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised? Annals of Surgical Oncology. PMID 28058550 DOI: 10.1245/S10434-016-5741-Y |
0.393 |
|
| 2017 |
Ho A, Barker CA, Gucalp A, Lebron-Zapata L, Wen YH, Phung A, Wilgucki M, Henrich M, Arnold B, Patil S, McArthur HL. Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer. Journal of Clinical Oncology. 35: 95-95. DOI: 10.1200/Jco.2017.35.7_Suppl.95 |
0.434 |
|
| 2017 |
Chow OS, Patil S, Keskin M, Smith JJ, Widmar M, Smith DD, Avila K, Shia J, Chu P, Garcia-Aguilar J. Institutional variation in the thoroughness of pathologic assessment and pathologic complete response rates for locally advanced rectal cancers treated with neoadjuvant chemoradiation. Journal of Clinical Oncology. 35: 696-696. DOI: 10.1200/Jco.2017.35.4_Suppl.696 |
0.396 |
|
| 2017 |
Blinder VS, Eberle CE, Aviki E, Schleicher SM, Patil S, Basch EM, Sloan JA, Bennett AV. A multicenter analysis of patient reported risk factors for not working during cancer therapy. Journal of Clinical Oncology. 35: 6523-6523. DOI: 10.1200/Jco.2017.35.15_Suppl.6523 |
0.379 |
|
| 2017 |
Wang R, Yu AF, Steingart R, Patil S, Baselga J, Norton L, Hudis C, Dang CT. Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer. Journal of Clinical Oncology. 35: 540-540. DOI: 10.1200/Jco.2017.35.15_Suppl.540 |
0.402 |
|
| 2017 |
Funt S, Patil S, Feldman DR, Motzer RJ, Bajorin DF, Sheinfeld J, Tickoo S, Reuter VE, Bosl GJ. Histologic determinants of long-term overall survival in patients (pts) with germ cell tumors (GCT). Journal of Clinical Oncology. 35: 4555-4555. DOI: 10.1200/Jco.2017.35.15_Suppl.4555 |
0.32 |
|
| 2017 |
McArthur H, Beal K, Halpenny D, Henrich M, Modi S, Patil S, Young R, Kaley T, Merghoub T, Barker C, Wong P, Hamilton N, Hudis C, Wolchok J, Norton L. Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM) Cancer Research. 77: 4705-4705. DOI: 10.1158/1538-7445.Am2017-4705 |
0.396 |
|
| 2016 |
Pilewskie M, Olcese C, Patil S, Van Zee KJ. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy? Annals of Surgical Oncology. PMID 27766556 DOI: 10.1245/S10434-016-5595-3 |
0.374 |
|
| 2016 |
Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. PMID 27622751 DOI: 10.1016/J.Clbc.2016.07.013 |
0.474 |
|
| 2016 |
Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, et al. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27601542 DOI: 10.1200/Jco.2016.67.9084 |
0.314 |
|
| 2016 |
Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon SB, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris EA, Brogi E, ... ... Patil S, et al. Deep Sequencing of T-Cell Receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunology Research. PMID 27587469 DOI: 10.1158/2326-6066.Cir-16-0013 |
0.409 |
|
| 2016 |
Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, Seidman AD. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clinical Breast Cancer. PMID 27569275 DOI: 10.1016/J.Clbc.2016.07.002 |
0.466 |
|
| 2016 |
McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, ... ... Patil S, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27566765 DOI: 10.1158/1078-0432.Ccr-16-0190 |
0.401 |
|
| 2016 |
Wen HY, Krystel-Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA, Brogi E. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up. Cancer. PMID 27526056 DOI: 10.1002/Cncr.30271 |
0.421 |
|
| 2016 |
Durando M, Gennaro L, Cho GY, Giri DD, Gnanasigamani MM, Patil S, Sutton EJ, Deasy JO, Morris EA, Thakur SB. Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer. European Journal of Radiology. 85: 1651-8. PMID 27501902 DOI: 10.1016/J.Ejrad.2016.06.019 |
0.387 |
|
| 2016 |
Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, DeLuca J, Lee CH, Hsieh JJ, Feldman DR, Motzer RJ, H Voss M. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. The Oncologist. PMID 27286790 DOI: 10.1634/Theoncologist.2016-0145 |
0.305 |
|
| 2016 |
Cronin PA, Olcese C, Patil S, Morrow M, Van Zee KJ. Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology. PMID 27198513 DOI: 10.1245/S10434-016-5249-5 |
0.374 |
|
| 2016 |
Mamtani A, Patil S, Van Zee KJ, Cody HS, Pilewskie M, Barrio AV, Heerdt AS, Morrow M. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. Annals of Surgical Oncology. PMID 27169771 DOI: 10.1245/S10434-016-5259-3 |
0.374 |
|
| 2016 |
Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, El-Tamer M, Gemignani ML, Heerdt AS, Sclafani LM, Sacchini V, Cody HS, Patil S, Morrow M. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Annals of Surgical Oncology. PMID 27160528 DOI: 10.1245/S10434-016-5246-8 |
0.402 |
|
| 2016 |
Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-Term Renal Outcomes after Cisplatin Treatment. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 27073199 DOI: 10.2215/Cjn.08070715 |
0.335 |
|
| 2016 |
Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Annals of Surgical Oncology. PMID 27020587 DOI: 10.1245/S10434-016-5205-4 |
0.341 |
|
| 2016 |
Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. The Oncologist. PMID 26984450 DOI: 10.1634/Theoncologist.2015-0321 |
0.406 |
|
| 2016 |
Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer. PMID 26859126 DOI: 10.1002/Cncr.29903 |
0.447 |
|
| 2016 |
Goldfarb SB, Kamer SA, Oppong BA, Eaton A, Patil S, Junqueira MJ, Olcese C, Kelvin JF, Gemignani ML. Fertility Preservation for the Young Breast Cancer Patient. Annals of Surgical Oncology. PMID 26790670 DOI: 10.1245/S10434-015-5036-8 |
0.445 |
|
| 2016 |
McArthur HL, Page DB, Proverbs-Singh TA, Solomon SB, Hudis CA, Norton L, Patil S, Barrett JA, Lebel FM. Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3097 |
0.442 |
|
| 2016 |
Gucalp A, Proverbs-Singh TA, Corben A, Moynahan ME, Patil S, Boyle LA, Hudis CA, Traina TA. Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 34: TPS1103-TPS1103. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps1103 |
0.412 |
|
| 2016 |
Traina TA, Plitas G, Reis-Filho JS, Morris EA, Hughes M, Sung JS, Patil S, Piscuoglio S, Park S, Greenberg C, Jonas O, Hudis CA, Baselga J. Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy. Journal of Clinical Oncology. 34: TPS1101-TPS1101. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps1101 |
0.38 |
|
| 2016 |
Lee C, Motzer RJ, Hoetker A, Akin O, Molina AM, Gold TM, Patil S, Janakiraman M, Gowrishankar B, Houldsworth J. Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16109 |
0.315 |
|
| 2016 |
Khasraw M, Mukaro VR, West L, White K, Rippy E, Brandt C, Tobler R, Murphy CC, Collins IM, Baron-Hay SE, Ashley DM, Patil S. Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer. Journal of Clinical Oncology. 34: e12515-e12515. DOI: 10.1200/Jco.2016.34.15_Suppl.E12515 |
0.435 |
|
| 2016 |
Blinder VS, Eberle CE, Patil S, Oeffinger KC, Bradley C, Gany F. Correlates of work status during adjuvant chemo- or radiation therapy for breast cancer. Journal of Clinical Oncology. 34: 6556-6556. DOI: 10.1200/Jco.2016.34.15_Suppl.6556 |
0.448 |
|
| 2016 |
Razavi P, Chang MT, Middha S, Ross DS, Zehir A, Proverbs-Singh TA, Kandoth C, Chandarlapaty S, Dickler MN, Reis-Filho JS, Patil S, Seshan V, Smyth L, Iyengar NM, Jhaveri K, et al. Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations Cancer Research. 76: 4509-4509. DOI: 10.1158/1538-7445.Am2016-4509 |
0.443 |
|
| 2016 |
Chaul-Barbosa C, Morikawa A, Patil S, Boire A, Jordan L, Rozner R, Seidman A, Pentsova E. BMET-30. TREATMENT OPTIONS OF LONG TERM SURVIVORS WITH LEPTOMENINGEAL METASTASES AND BREAST CANCER Neuro-Oncology. 18: vi33-vi33. DOI: 10.1093/Neuonc/Now212.130 |
0.405 |
|
| 2016 |
McArthur H, Page D, Proverbs-Singh T, Solomon S, Hudis C, Norton L, Patil S, Henrich M, Halpenny D, Erinjeri J, Yuan J, Wong P, Jones C, Escudero M, Cai H, et al. Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients Annals of Oncology. 27: vi87. DOI: 10.1093/Annonc/Mdw365.59 |
0.322 |
|
| 2015 |
Subhedar P, Olcese C, Patil S, Morrow M. Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 32. PMID 28147784 DOI: 10.1200/Jco.2015.33.28_Suppl.32 |
0.402 |
|
| 2015 |
Pilewskie M, Jochelson M, Gooch JC, Patil S, Stempel M, Morrow M. Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection? Journal of the American College of Surgeons. PMID 26711795 DOI: 10.1016/J.Jamcollsurg.2015.11.013 |
0.311 |
|
| 2015 |
Bloomquist EV, Ajkay N, Patil S, Collett AE, Frazier TG, Barrio AV. A Randomized Prospective Comparison of Patient-Assessed Satisfaction and Clinical Outcomes with Radioactive Seed Localization versus Wire Localization. The Breast Journal. PMID 26696461 DOI: 10.1111/Tbj.12564 |
0.393 |
|
| 2015 |
Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, ... Patil S, et al. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. PMID 26454612 DOI: 10.1016/J.Clbc.2015.09.009 |
0.441 |
|
| 2015 |
Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ. Erratum to: Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology. PMID 26419587 DOI: 10.1245/S10434-015-4884-6 |
0.374 |
|
| 2015 |
Lee CH, Hötker AM, Voss MH, Feldman DR, Woo KM, Patil S, Coskey DT, Akin O, Hsieh JJ, Motzer RJ. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical Genitourinary Cancer. PMID 26404107 DOI: 10.1016/J.Clgc.2015.07.010 |
0.337 |
|
| 2015 |
King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA, et al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26371145 DOI: 10.1200/Jco.2015.61.4743 |
0.434 |
|
| 2015 |
Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years. Annals of Surgery. 262: 623-31. PMID 26366541 DOI: 10.1097/Sla.0000000000001454 |
0.355 |
|
| 2015 |
Karsten M, Stempel M, Radosa J, Patil S, King TA. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. Annals of Surgical Oncology. PMID 26340863 DOI: 10.1245/S10434-015-4841-4 |
0.437 |
|
| 2015 |
O'Brien JA, Ho A, Wright GP, Stempel M, Patil S, Krause K, Morrow M, Gemignani ML. Breast-Conserving Surgery in Bilateral Breast Cancer. Annals of Surgical Oncology. 22: 3389-96. PMID 26265365 DOI: 10.1245/S10434-015-4746-2 |
0.45 |
|
| 2015 |
Subhedar P, Olcese C, Patil S, Morrow M, J Van Zee K. Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology. 22: 3273-81. PMID 26215193 DOI: 10.1245/S10434-015-4740-8 |
0.394 |
|
| 2015 |
Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, Kumar AS, Oommen S, Coutsoftides T, Hunt SR, Stamos MJ, Ternent CA, Herzig DO, Fichera A, Polite BN, ... ... Patil S, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. The Lancet. Oncology. PMID 26187751 DOI: 10.1016/S1470-2045(15)00004-2 |
0.361 |
|
| 2015 |
Meisel JL, Woo KM, Sudarsan N, Eng J, Patil S, Jacobsen EP, Murali R, Gardner GJ, Bosl GJ, Aghajanian C, Feldman DR. Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecologic Oncology. 138: 566-72. PMID 26115974 DOI: 10.1016/J.Ygyno.2015.06.029 |
0.329 |
|
| 2015 |
Feldman DR, Glezerman I, Patil S, Van Alstine L, Bajorin DF, Fischer P, Hughes A, Sheinfeld J, Bains M, Reich L, Woo K, Giralt S, Bosl GJ, Motzer RJ. Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical Genitourinary Cancer. PMID 26072101 DOI: 10.1016/J.Clgc.2015.05.003 |
0.323 |
|
| 2015 |
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, et al. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2722-9. PMID 25779953 DOI: 10.1158/1078-0432.Ccr-14-2780 |
0.449 |
|
| 2015 |
Peterson CY, Weiser MR, Paty PB, Guillem JG, Nash GM, Garcia-Aguilar J, Patil S, Temple LK. Does endoscopic ultrasound improve detection of locally recurrent anal squamous-cell cancer? Diseases of the Colon and Rectum. 58: 193-8. PMID 25585077 DOI: 10.1097/Dcr.0000000000000291 |
0.368 |
|
| 2015 |
Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, ... Patil S, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 442-7. PMID 25547504 DOI: 10.1200/Jco.2014.57.1745 |
0.418 |
|
| 2015 |
Manning AT, Eaton A, Azu M, Sampson M, Patil S, Godfrey D, Beesen AA, Liberman L, Gemignani ML. Breast cancer screening at the Breast Examination Center of Harlem. Annals of Surgical Oncology. 22: 2026-33. PMID 25448800 DOI: 10.1245/S10434-014-4240-2 |
0.441 |
|
| 2015 |
Bastos DA, Molina AM, Hatzoglou V, Jia X, Velasco S, Patil S, Voss MH, Feldman DR, Motzer RJ. Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. Clinical Genitourinary Cancer. 13: 59-66. PMID 25023939 DOI: 10.1016/J.Clgc.2014.06.002 |
0.369 |
|
| 2015 |
Lee C, Hoetker AM, Voss MH, Feldman DR, Woo K, Patil S, Coskey DT, Akin O, Hsieh J, Motzer RJ. Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugs. Journal of Clinical Oncology. 33: 468-468. DOI: 10.1200/Jco.2015.33.7_Suppl.468 |
0.367 |
|
| 2015 |
Voss MH, Chen Y, Chaim J, Coskey DT, Woo K, Patil S, Molina AM, Hsieh J, Motzer RJ, Feldman DR. A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer. Journal of Clinical Oncology. 33: 411-411. DOI: 10.1200/Jco.2015.33.7_Suppl.411 |
0.392 |
|
| 2015 |
Blinder VS, Eberle CE, Patil S, Ramirez J, McNish T, Min S, Bhagwati N, Lee S, Hudis CA, Oeffinger KC, Gany F. Ethnic disparities in the impact of breast cancer on the workforce: A pilot study. Journal of Clinical Oncology. 33: e17600-e17600. DOI: 10.1200/Jco.2015.33.15_Suppl.E17600 |
0.414 |
|
| 2015 |
Proverbs-Singh TA, Cadoo KA, Torre G, Patil S, Gucalp A, Dang CT, Hudis CA, Glezerman IG, Traina TA. Prevalence of hypomagnesemia in patients with HER2–positive breast cancer receiving pertuzumab treatment. Journal of Clinical Oncology. 33: e11608-e11608. DOI: 10.1200/Jco.2015.33.15_Suppl.E11608 |
0.397 |
|
| 2015 |
Goldfarb SB, Bedoschi G, Grunblatt E, Goswami S, Cigler T, Quistorff J, Pacheco F, Stobezki R, Robson ME, Moy F, Hudis CA, Patil S, Dickler MN, Oktay K. The impact of adjuvant breast cancer (BC) chemotherapy on ovarian reserve and menses. Journal of Clinical Oncology. 33: 9522-9522. DOI: 10.1200/Jco.2015.33.15_Suppl.9522 |
0.35 |
|
| 2015 |
Argolo DFSDTE, Smyth LM, Iyengar NM, Patil S, Norton L, Baselga J, Hudis CA, Dang CT. Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center. Journal of Clinical Oncology. 33: 616-616. DOI: 10.1200/Jco.2015.33.15_Suppl.616 |
0.416 |
|
| 2015 |
Page DB, Wen YH, Brogi E, Yuan J, Emerson RO, Patil S, Dang CT, Norton L, Hudis CA, McArthur HL. Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer. Journal of Clinical Oncology. 33: 609-609. DOI: 10.1200/Jco.2015.33.15_Suppl.609 |
0.333 |
|
| 2015 |
Smyth LM, Iyengar NM, Chandarlapaty S, Sugarman S, Comen EA, Drullinsky P, Sklarin NT, Traina TA, Troso-Sandoval TA, Patil S, Wasserheit-Lieblich C, Argolo DFSDTE, Baselga J, Norton L, Hudis CA, et al. Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. Journal of Clinical Oncology. 33: 607-607. DOI: 10.1200/Jco.2015.33.15_Suppl.607 |
0.415 |
|
| 2015 |
Page DB, Mariotti V, Davydov O, Patil S, Hans D, Hudis CA, Farooki A, Fornier MN. A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI). Journal of Clinical Oncology. 33: 574-574. DOI: 10.1200/Jco.2015.33.15_Suppl.574 |
0.344 |
|
| 2015 |
Pilewskie ML, Olcese C, Patil S, Van Zee KJ. Long-term rates of ipsilateral breast tumor recurrence (IBTR) for women with ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria undergoing standard therapy. Journal of Clinical Oncology. 33: 560-560. DOI: 10.1200/Jco.2015.33.15_Suppl.560 |
0.415 |
|
| 2015 |
Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences based on germline mutation status and potential implications for adjuvant systemic therapy (AST). Journal of Clinical Oncology. 33: 519-519. DOI: 10.1200/Jco.2015.33.15_Suppl.519 |
0.402 |
|
| 2015 |
Lee C, Motzer R, Hoetker A, Akin O, Molina AM, Gold TM, Patil S, Gowrishankar B, Houldsworth J. Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 33: 4552-4552. DOI: 10.1200/Jco.2015.33.15_Suppl.4552 |
0.318 |
|
| 2015 |
Voss MH, Chen Y, Chaim J, Coskey DT, Woo K, Redzematovic A, Wang P, Lee W, Patil S, Molina AM, Hsieh J, Motzer R, Feldman DR. A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features. Journal of Clinical Oncology. 33: 4522-4522. DOI: 10.1200/Jco.2015.33.15_Suppl.4522 |
0.367 |
|
| 2015 |
Morikawa A, Jordan L, Rozner R, Patil S, Boire AA, Pentsova E, Seidman AD. Characteristics and outcomes of breast cancer patients with leptomeningeal metastasis at Memorial Sloan Kettering Cancer Center (MSKCC). Journal of Clinical Oncology. 33: 2026-2026. DOI: 10.1200/Jco.2015.33.15_Suppl.2026 |
0.472 |
|
| 2015 |
Page DB, Diab A, Yuan J, Dong Z, Soloman SB, Patil S, Hudis CA, Wolchok JD, Norton L, McArthur HL. Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S1-O6 |
0.389 |
|
| 2015 |
Shah PD, Moynahan ME, Modi S, Caravella BA, Datko FM, Zamora S, Comen E, Gilewski T, Sugarman SM, D'Andrea G, Lake DE, Goldfarb SB, Patil S, Covey A, Berger MF, et al. Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd5-3 |
0.354 |
|
| 2015 |
Gooch JC, Guerini-Rocco E, Patil S, Koslow SB, Brot MD, Park AY, Boafo CA, Reis-Filho JS, King TA. Abstract P6-13-02: The extent of lobular carcinoma in situ (LCIS) at surgical excision predicts for the development of subsequent breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-13-02 |
0.457 |
|
| 2015 |
Jhaveri K, Cadoo K, Chandarlapaty S, Teplinsky E, Speyer J, Andrea GD, Patil S, Haque S, Friedman K, Heese S, Neville D, Esteva F, Hudis C, Modi S. Abstract P5-19-23: A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-19-23 |
0.459 |
|
| 2015 |
Gajria D, Modi S, Saura C, Sakr R, Solano K, Won H, Pannu H, Patil S, Lake D, Traina T, King T, Berger M, Baselga J, Rosen N, Hudis C, et al. Abstract P5-19-04: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-19-04 |
0.45 |
|
| 2015 |
Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, ... ... Patil S, et al. Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-15-01 |
0.354 |
|
| 2015 |
Goldfarb SB, Bedoschi G, Grunblatt E, Goswami S, Cigler T, Quistorff J, Pacheco F, Stobezki R, Robson M, Moy F, Hudis C, Patil S, Dickler M, Oktay K. Abstract P1-09-06: A prospective longitudinal study of the impact of breast cancer treatment with adjuvant chemotherapy or tamoxifen alone on ovarian reserve Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-09-06 |
0.424 |
|
| 2015 |
Shah PD, Moynahan ME, Modi S, Hamilton N, Caravella BA, Zamora S, Dang C, Gilewski T, Traina T, Comen E, Sugarman SM, D'Andrea G, Lake D, Goldfarb S, Patil S, et al. Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct330 |
0.327 |
|
| 2014 |
Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Sacchini V, Morrow M, Brogi E, Morris EA, Patil S, Robins H, Wolchok JD, et al. Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 64. PMID 28141090 DOI: 10.1200/Jco.2014.32.26_Suppl.64 |
0.354 |
|
| 2014 |
Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, Adusumilli PS, Wen HY. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. Plos One. 9: e114900. PMID 25506917 DOI: 10.1371/Journal.Pone.0114900 |
0.44 |
|
| 2014 |
Ugras S, Stempel M, Patil S, Morrow M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Annals of Surgical Oncology. 21: 3780-6. PMID 24952028 DOI: 10.1245/S10434-014-3851-Y |
0.442 |
|
| 2014 |
Oppong BA, Pharmer LA, Oskar S, Eaton A, Stempel M, Patil S, King TA. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Medicine. 3: 1025-34. PMID 24944108 DOI: 10.1002/Cam4.259 |
0.374 |
|
| 2014 |
Sung JS, Li J, Da Costa G, Patil S, Van Zee KJ, Dershaw DD, Morris EA. Preoperative breast MRI for early-stage breast cancer: effect on surgical and long-term outcomes. Ajr. American Journal of Roentgenology. 202: 1376-82. PMID 24848838 DOI: 10.2214/Ajr.13.11355 |
0.46 |
|
| 2014 |
Damast S, Alektiar K, Eaton A, Gerber NK, Goldfarb S, Patil S, Jia R, Leitao M, Carter J, Basch E. Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer. Annals of Surgical Oncology. 21: 2740-54. PMID 24619493 DOI: 10.1245/S10434-014-3562-4 |
0.325 |
|
| 2014 |
Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haque S, ... Patil S, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical Breast Cancer. 14: 154-60. PMID 24512858 DOI: 10.1016/J.Clbc.2013.12.012 |
0.413 |
|
| 2014 |
Moo TA, McMillan R, Lee M, Stempel M, Ho A, Patil S, El-Tamer M. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes. Annals of Surgical Oncology. 21: 1569-74. PMID 24488216 DOI: 10.1245/S10434-014-3488-X |
0.394 |
|
| 2014 |
Sweldens C, Peeters S, van Limbergen E, Janssen H, Laenen A, Patil S, Van Zee KJ, Weltens C. Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Cancer Journal (Sudbury, Mass.). 20: 1-7. PMID 24445756 DOI: 10.1097/Ppo.0000000000000025 |
0.455 |
|
| 2014 |
Pilewskie M, Olcese C, Eaton A, Patil S, Morris E, Morrow M, Van Zee KJ. Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Annals of Surgical Oncology. 21: 1552-60. PMID 24385207 DOI: 10.1245/S10434-013-3424-5 |
0.421 |
|
| 2014 |
Pilewskie M, Ho A, Orell E, Stempel M, Chen Y, Eaton A, Patil S, Morrow M. Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy. Annals of Surgical Oncology. 21: 1209-14. PMID 24327132 DOI: 10.1245/S10434-013-3416-5 |
0.447 |
|
| 2014 |
Sim HW, Morris PG, Patil S, Khasraw M. Brain metastases in breast cancer. Expert Review of Anticancer Therapy. 14: 173-83. PMID 24308683 DOI: 10.1586/14737140.2014.863468 |
0.407 |
|
| 2014 |
Bokacheva L, Kaplan JB, Giri DD, Patil S, Gnanasigamani M, Nyman CG, Deasy JO, Morris EA, Thakur SB. Intravoxel incoherent motion diffusion-weighted MRI at 3.0 T differentiates malignant breast lesions from benign lesions and breast parenchyma. Journal of Magnetic Resonance Imaging : Jmri. 40: 813-23. PMID 24273096 DOI: 10.1002/Jmri.24462 |
0.302 |
|
| 2014 |
Moo TA, Choi L, Culpepper C, Olcese C, Heerdt A, Sclafani L, King TA, Reiner AS, Patil S, Brogi E, Morrow M, Van Zee KJ. Impact of margin assessment method on positive margin rate and total volume excised. Annals of Surgical Oncology. 21: 86-92. PMID 24046114 DOI: 10.1245/S10434-013-3257-2 |
0.354 |
|
| 2014 |
Dengel LT, Van Zee KJ, King TA, Stempel M, Cody HS, El-Tamer M, Gemignani ML, Sclafani LM, Sacchini VS, Heerdt AS, Plitas G, Junqueira M, Capko D, Patil S, Morrow M. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Annals of Surgical Oncology. 21: 22-7. PMID 23975314 DOI: 10.1245/S10434-013-3200-6 |
0.433 |
|
| 2014 |
Bastos DA, Molina AM, Jia X, Velasco S, Patil S, Voss MH, Feldman DR, Motzer RJ. Safety and efficacy of targeted therapy for renal cell carcinoma (RCC) with brain metastasis. Journal of Clinical Oncology. 32: 497-497. DOI: 10.1200/Jco.2014.32.4_Suppl.497 |
0.349 |
|
| 2014 |
Feldman DR, Stadler WM, Appleman LJ, Quinn DI, Costello BA, Schwartz GK, Reuter VE, Woo K, Patil S, Fusco A, Smith SC, Carlson J, Bosl GJ, Motzer RJ. Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR). Journal of Clinical Oncology. 32: 364-364. DOI: 10.1200/Jco.2014.32.4_Suppl.364 |
0.321 |
|
| 2014 |
Morikawa A, Jhaveri KL, Patil S, Chen M, McDonnell E, Neville DA, Mak FM, Gansukh B, John HL, Holodny A, Schöder H, Beal K, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging to evaluate treatment response after WBRT sorafenib. Journal of Clinical Oncology. 32: TPS2103-TPS2103. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2103 |
0.361 |
|
| 2014 |
Khasraw M, Mukaro VR, West L, Brandt C, Woollett AM, Edwards M, Spokes R, Mitchell G, Prince K, Hayes TM, Collins IM, Guminski AD, Baron-Hay SE, Olesen IH, Bryan J, ... ... Patil S, et al. Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1135 |
0.412 |
|
| 2014 |
Iyengar NM, Fornier MN, Sugarman S, Theodoulou M, Troso-Sandoval TA, D'Andrea G, Drullinsky P, Fasano J, Gajria D, Goldfarb SB, Comen EA, Lake D, Modi S, Traina TA, Chen M, ... Patil S, et al. Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC). Journal of Clinical Oncology. 32: 633-633. DOI: 10.1200/Jco.2014.32.15_Suppl.633 |
0.315 |
|
| 2014 |
Meisel JL, Woo K, Sudarsan N, Eng J, Patil S, Jacobsen EP, Murali R, Motzer RJ, Bosl GJ, Aghajanian C, Feldman DR. Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC) experience. Journal of Clinical Oncology. 32: 5539-5539. DOI: 10.1200/Jco.2014.32.15_Suppl.5539 |
0.323 |
|
| 2014 |
Moynahan ME, Sung P, Asham M, Zamora S, Shah PD, Modi S, Lake D, D'Andrea G, Goldfarb SB, Chandarlapaty S, Hudis CA, Baselga J, Dickler MN, Patil S, Gaskell AA. Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K{alpha}-inhibitor plus letrozole (L) or exemestane (E). Journal of Clinical Oncology. 32: 517-517. DOI: 10.1200/Jco.2014.32.15_Suppl.517 |
0.322 |
|
| 2014 |
Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, et al. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). Journal of Clinical Oncology. 32: 3021-3021. DOI: 10.1200/Jco.2014.32.15_Suppl.3021 |
0.345 |
|
| 2014 |
Shah PD, Modi S, Datko FM, Moynahan ME, Zamora S, D'Andrea G, Lake D, Goldfarb SB, Patil S, Singh S, Langley EJ, Kim PS, Covey AM, Caravella BA, Berger MF, et al. Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 32: 2605-2605. DOI: 10.1200/Jco.2014.32.15_Suppl.2605 |
0.356 |
|
| 2014 |
Page DB, McArthur H, Dong Z, Wong P, Emerson R, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, ... ... Patil S, et al. Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P138 |
0.375 |
|
| 2014 |
Oktay K, Goldfarb S, Bedoschi G, Quistorff J, Grunblatt E, Cigler T, Moy F, Patil S, Goswami S, Dickler M. A prospective longitudinal study of the impact of breast cancer chemotherapy on ovarian reserve: do individuals have differing susceptibilities? Fertility and Sterility. 102: e151. DOI: 10.1016/j.fertnstert.2014.07.517 |
0.319 |
|
| 2013 |
Voss MH, Karlo C, Ajeti A, Patil S, Feldman DR, Molina AM, Motzer RJ. mTOR inhibitor therapy for metastatic sarcomatoid clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 450. PMID 28137073 DOI: 10.1200/Jco.2013.31.6_Suppl.450 |
0.329 |
|
| 2013 |
Hu J, Dorff TB, Patil S, Van Alstine LJ, Momen L, Carousso M, Hughes A, Snively-Solomon J, Ketchens C, Sheinfeld J, Bains MS, Bajorin DF, Bosl GJ, Motzer RJ, Quinn DI. Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 336. PMID 28137042 DOI: 10.1200/Jco.2013.31.6_Suppl.336 |
0.343 |
|
| 2013 |
Bastos DA, Karlo C, Patil S, Ajeti A, Hakimi AA, Feldman DR, Molina AM, Berger MF, Hsieh J, Motzer RJ. Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 391. PMID 28136739 DOI: 10.1200/Jco.2013.31.6_Suppl.391 |
0.322 |
|
| 2013 |
Solomon SB, Comstock C, Maybody M, Sacchini V, Durack JC, Blum B, Yuan J, Patil S, Neville DA, Sung JS, Kotin A, Morris EA, Brogi E, Morrow M, Wolchok JD, et al. A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 67. PMID 28136692 DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3120 |
0.377 |
|
| 2013 |
Olcese C, Eaton A, Patil S, Morris EA, Morrow M, Van Zee KJ. Association of MRI and locoregional recurrence (LRR) rates in ductal carcinoma in situ (DCIS) patients treated with or without radiation therapy (RT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 57. PMID 28136658 DOI: 10.1200/Jco.2013.31.26_Suppl.57 |
0.388 |
|
| 2013 |
Diab A, Patil S, Forte V, Blum B, Young RJ, Beal K, Hudis C, Seidman AD, McArthur HL. Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 144. PMID 28136531 DOI: 10.1200/Jco.2013.31.26_Suppl.144 |
0.452 |
|
| 2013 |
Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Medicine. 2: 725-33. PMID 24403238 DOI: 10.1002/Cam4.119 |
0.364 |
|
| 2013 |
King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Research and Treatment. 142: 445-53. PMID 24141896 DOI: 10.1007/S10549-013-2725-5 |
0.432 |
|
| 2013 |
Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 119: 3943-51. PMID 24037735 DOI: 10.1002/Cncr.28284 |
0.458 |
|
| 2013 |
Moo TA, McMillan R, Lee M, Stempel M, Patil S, Ho A, El-Tamer M. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes. Annals of Surgical Oncology. 20: 3169-74. PMID 23975289 DOI: 10.1245/S10434-013-3117-0 |
0.334 |
|
| 2013 |
Gemignani ML, Patil S, Seshan VE, Sampson M, Humm JL, Lewis JS, Brogi E, Larson SM, Morrow M, Pandit-Taskar N. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1697-702. PMID 23970364 DOI: 10.2967/Jnumed.112.113373 |
0.416 |
|
| 2013 |
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, ... ... Patil S, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5505-12. PMID 23965901 DOI: 10.1158/1078-0432.Ccr-12-3327 |
0.404 |
|
| 2013 |
Blinder V, Patil S, Eberle C, Griggs J, Maly RC. Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study. Breast Cancer Research and Treatment. 140: 407-16. PMID 23884596 DOI: 10.1007/S10549-013-2625-8 |
0.398 |
|
| 2013 |
Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 11: 297-302. PMID 23707221 DOI: 10.1016/J.Clgc.2013.04.001 |
0.332 |
|
| 2013 |
Perez CA, Zumsteg ZS, Gupta G, Morrow M, Arnold B, Patil SM, Traina TA, Robson ME, Wen YH, McCormick B, Powell SN, Ho AY. Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast Cancer Research and Treatment. 139: 497-506. PMID 23645006 DOI: 10.1007/S10549-013-2550-X |
0.324 |
|
| 2013 |
Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer. 119: 1344-8. PMID 23165893 DOI: 10.1002/Cncr.27842 |
0.418 |
|
| 2013 |
Choi DX, Eaton AA, Olcese C, Patil S, Morrow M, Van Zee KJ. Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer? Annals of Surgical Oncology. 20: 1302-10. PMID 23161115 DOI: 10.1245/S10434-012-2719-2 |
0.394 |
|
| 2013 |
Kapoor NS, Eaton A, King TA, Patil S, Stempel M, Morris E, Brogi E, Morrow M. Should breast density influence patient selection for breast-conserving surgery? Annals of Surgical Oncology. 20: 600-6. PMID 22941162 DOI: 10.1245/S10434-012-2604-Z |
0.419 |
|
| 2013 |
Sugaya L, Filho PRdA, Mota BS, Patil S, Zee KJV, Bevilacqua JLB. A Comparison of Breast Surgeon and Nomogram-Generated Risk Predictions of Sentinel and Non-Sentinel Node Metastases Journal of Cancer Therapy. 4: 1-6. DOI: 10.4236/Jct.2013.47A001 |
0.439 |
|
| 2013 |
Patil S, Blinder VS, Gany F, Maly RC. Predictors of adequate financial resources 5 years after breast cancer diagnosis in low-income women. Journal of Clinical Oncology. 31: e20620-e20620. DOI: 10.1200/Jco.2013.31.15_Suppl.E20620 |
0.396 |
|
| 2013 |
Bastos DA, Molina AM, Jia X, Velasco S, Patil S, Voss MH, Feldman DR, Motzer RJ. Targeted therapy for renal cell carcinoma (RCC) with brain metastasis: Overall survival (OS) and safety. Journal of Clinical Oncology. 31: e15517-e15517. DOI: 10.1200/Jco.2013.31.15_Suppl.E15517 |
0.36 |
|
| 2013 |
Goldfarb SB, Dickler MN, Dnistrian AM, Patil S, Dunn L, Chang K, Berkowitz AP, Tucker N, Carter J, Barakat RR, Hudis C, Castiel M. Use of intravaginal 17-β estradiol to improve sexual function and menopausal symptoms in postmenopausal women with breast cancer on aromatase inhibitors. Journal of Clinical Oncology. 31: 9610-9610. DOI: 10.1200/Jco.2013.31.15_Suppl.9610 |
0.318 |
|
| 2013 |
Blinder VS, Patil S, Gany F, Maly RC. Five-year trajectories of financial recovery in low-income breast cancer survivors. Journal of Clinical Oncology. 31: 9597-9597. DOI: 10.1200/Jco.2013.31.15_Suppl.9597 |
0.418 |
|
| 2013 |
Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman RJ, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis C, Dang CT. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal of Clinical Oncology. 31: 167-167. DOI: 10.1200/Jco.2013.31.15_Suppl.630 |
0.36 |
|
| 2013 |
Jia X, Feldman DR, Glezerman I, Van Alstine LJ, Bajorin DF, Fischer P, Hughes A, Sheinfeld J, Bains MS, Reich L, Bosl GJ, Motzer RJ, Patil S. Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT). Journal of Clinical Oncology. 31: 4534-4534. DOI: 10.1200/Jco.2013.31.15_Suppl.4534 |
0.316 |
|
| 2013 |
Vaklavas C, Abramson VG, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Li Y, Patil S, Hayes DF, Poznak CHV, Nangia JR, Irvin WJ, Krontiras H, et al. TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC). Journal of Clinical Oncology. 31: 1052-1052. DOI: 10.1200/Jco.2013.31.15_Suppl.1052 |
0.441 |
|
| 2013 |
Pilewskie ML, Ho AY, Orell E, Stempel M, Chen Y, Eaton A, Patil S, Morrow M. Effect of margin width on local recurrence (LR) in triple-negative (TN) breast cancer treated with breast-conserving therapy (BCT). Journal of Clinical Oncology. 31: 1021-1021. DOI: 10.1200/Jco.2013.31.15_Suppl.1021 |
0.488 |
|
| 2013 |
Dengel L, Cody HS, King TA, Van Zee KJ, Patil S, Corben A, El-Tamer M, Stempel M, Sclafani LM, Heerdt AS, Gemignani M, Capko D, Sacchini V, Plitas G, Morrow M. The presence and extent of extracapsular extension (ECE) and the need for axillary lymph node dissection (ALND) in patients who meet ACOSOG Z11 eligibility criteria. Journal of Clinical Oncology. 31: 1019-1019. DOI: 10.1200/Jco.2013.31.15_Suppl.1019 |
0.362 |
|
| 2012 |
D'Andrea G, Dickler MN, Theodoulou M, Goldfarb SB, Lake D, Fornier MN, Modi S, Sklarin NT, Comen EA, Fasano J, Gajria D, Drullinsky P, Murphy CG, Syldor A, Patil S, et al. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 134. PMID 28146802 DOI: 10.1200/Jco.2012.30.27_Suppl.134 |
0.375 |
|
| 2012 |
Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6784-91. PMID 23092874 DOI: 10.1158/1078-0432.Ccr-12-1785 |
0.409 |
|
| 2012 |
Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R, Motzer RJ. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. The Journal of Urology. 188: 2095-100. PMID 23083849 DOI: 10.1016/J.Juro.2012.08.026 |
0.373 |
|
| 2012 |
Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited overall survival in patients with brain metastases from triple negative breast cancer. The Breast Journal. 18: 345-50. PMID 22607041 DOI: 10.1111/J.1524-4741.2012.01246.X |
0.464 |
|
| 2012 |
Damast S, Alektiar KM, Goldfarb S, Eaton A, Patil S, Mosenkis J, Bennett A, Atkinson T, Jewell E, Leitao M, Barakat R, Carter J, Basch E. Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 84: e187-93. PMID 22572074 DOI: 10.1016/J.Ijrobp.2012.03.030 |
0.302 |
|
| 2012 |
Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α. British Journal of Cancer. 106: 1587-90. PMID 22568998 DOI: 10.1038/Bjc.2012.149 |
0.341 |
|
| 2012 |
Wen YH, Ho A, Patil S, Akram M, Catalano J, Eaton A, Norton L, Benezra R, Brogi E. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Research and Treatment. 135: 93-102. PMID 22538771 DOI: 10.1007/S10549-012-2070-0 |
0.405 |
|
| 2012 |
Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, Larson S, Hudis CA, McArthur HL, Jochelson MS. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer. 118: 5454-62. PMID 22517371 DOI: 10.1002/Cncr.27579 |
0.34 |
|
| 2012 |
Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer. 118: 4944-52. PMID 22392492 DOI: 10.1002/cncr.27480 |
0.363 |
|
| 2012 |
Murphy CG, Mallam D, Stein S, Patil S, Howard J, Sklarin N, Hudis CA, Gemignani ML, Seidman AD. Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer. 118: 3254-9. PMID 22086863 DOI: 10.1002/Cncr.26654 |
0.406 |
|
| 2012 |
Blinder VS, Patil S, Thind A, Diamant A, Hudis CA, Basch E, Maly RC. Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study. Cancer. 118: 1664-74. PMID 22009703 DOI: 10.1002/Cncr.26478 |
0.379 |
|
| 2012 |
Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 131: 111-6. PMID 21898114 DOI: 10.1007/S10549-011-1749-Y |
0.429 |
|
| 2012 |
Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer. 118: 1982-8. PMID 21887681 DOI: 10.1002/Cncr.26484 |
0.437 |
|
| 2012 |
Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 118: 981-6. PMID 21792865 DOI: 10.1002/Cncr.26375 |
0.351 |
|
| 2012 |
Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Investigational New Drugs. 30: 335-40. PMID 20711632 DOI: 10.1007/S10637-010-9491-6 |
0.367 |
|
| 2012 |
Junqueira MJ, Goldfarb SB, Oppong BA, Patil S, Eaton A, Olcese C, Morgan J, Kelvin JF, Dickler MN, Gemignani M. Fertility preservation options and the young breast cancer patient: A survey. Journal of Clinical Oncology. 30: 575-575. DOI: 10.1200/Jco.2012.30.15_Suppl.575 |
0.365 |
|
| 2012 |
Pesce C, Stempel M, Eaton A, Patil S, Brogi E, Potz B, Hudis C, El-Tamer M. Predicting the Oncotype DX score: An inexpensive guesstimation. Journal of Clinical Oncology. 30: 557-557. DOI: 10.1200/Jco.2012.30.15_Suppl.557 |
0.338 |
|
| 2012 |
Feldman DR, Voss MH, Jia X, Van Alstine LJ, Patil S, Fischer P, Sheinfeld J, Bosl GJ, Motzer RJ. Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts). Journal of Clinical Oncology. 30: 4532-4532. DOI: 10.1200/Jco.2012.30.15_Suppl.4532 |
0.322 |
|
| 2012 |
Moo T, McMillan R, Lee M, Stempel M, Patil S, Ho AY, El-Tamer M. Predictors of recurrence in postmastectomy patients with one to three positive lymph nodes. Journal of Clinical Oncology. 30: 1118-1118. DOI: 10.1200/Jco.2012.30.15_Suppl.1118 |
0.426 |
|
| 2012 |
Jhaveri KL, Iyengar NM, Corben A, Patil S, Akram M, Towers R, Sakr R, Hudis C, King TA, Rosen N, Chandarlapaty S, Modi S. Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i). Journal of Clinical Oncology. 30: 10618-10618. DOI: 10.1200/Jco.2012.30.15_Suppl.10618 |
0.316 |
|
| 2012 |
Gucalp A, Tolaney SM, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell KL, Rugo HS, Nabell L, Forero-Torres A, Stearns V, Momen L, Gonzalez J, Giri DD, Patil S, et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). Journal of Clinical Oncology. 30: 1006-1006. DOI: 10.1200/Jco.2012.30.15_Suppl.1006 |
0.351 |
|
| 2011 |
Patil S, Manola J, Elson P, Bro W, Negrier S, Escudier B, Bukowski RM, Motzer RJ. Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4554. PMID 28023366 DOI: 10.1200/Jco.2011.29.15_Suppl.4554 |
0.373 |
|
| 2011 |
Gucalp A, Tolaney SM, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell KL, Rugo HS, Nabell L, Abbruzzi A, Gonzalez J, Giri DD, Patil S, Feigin K, D'Andrea G, et al. TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS122. PMID 28022944 DOI: 10.1200/jco.2011.29.15_suppl.tps122 |
0.302 |
|
| 2011 |
Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis C, Traina TA. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical Breast Cancer. 11: 306-11. PMID 21729667 DOI: 10.1016/J.Clbc.2011.03.021 |
0.444 |
|
| 2011 |
McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 117: 5461-8. PMID 21681735 DOI: 10.1002/Cncr.26171 |
0.433 |
|
| 2011 |
Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Research and Treatment. 129: 635-43. PMID 21617917 DOI: 10.1007/S10549-011-1601-4 |
0.428 |
|
| 2011 |
Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5132-9. PMID 21558407 DOI: 10.1158/1078-0432.Ccr-11-0072 |
0.416 |
|
| 2011 |
King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2158-64. PMID 21464413 DOI: 10.1200/Jco.2010.29.4041 |
0.451 |
|
| 2011 |
Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, Akram M, Nehhozina T, Jhaveri KL, Hudis CA, Seidman AD. Breast carcinoma with brain metastases: Clinical analysis and immunoprofile on tissue microarrays Annals of Oncology. 22: 2597-2603. PMID 21427063 DOI: 10.1093/Annonc/Mdr022 |
0.438 |
|
| 2011 |
Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer. 117: 4125-31. PMID 21387266 DOI: 10.1002/Cncr.25992 |
0.444 |
|
| 2011 |
King TA, Gurevich I, Sakr R, Patil S, Stempel M, Morrow M. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Annals of Surgery. 254: 2-7. PMID 21372684 DOI: 10.1097/Sla.0B013E3182125B26 |
0.485 |
|
| 2011 |
Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3490-9. PMID 21372222 DOI: 10.1158/1078-0432.Ccr-10-1359 |
0.366 |
|
| 2011 |
McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, et al. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3398-407. PMID 21350003 DOI: 10.1158/1078-0432.Ccr-10-1969 |
0.41 |
|
| 2011 |
Neuman HB, Patil S, Fuzesi S, Wong WD, Weiser MR, Guillem JG, Paty PB, Nash GM, Temple LK. Impact of a temporary stoma on the quality of life of rectal cancer patients undergoing treatment. Annals of Surgical Oncology. 18: 1397-403. PMID 21128000 DOI: 10.1245/S10434-010-1446-9 |
0.344 |
|
| 2011 |
Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. American Journal of Clinical Oncology. 34: 454-9. PMID 21127411 DOI: 10.1097/Coc.0B013E3181F47Aa4 |
0.306 |
|
| 2011 |
Marti JL, Dauer LT, Stempel M, Patil S, Kaplan JB, Montgomery LL. Cumulative imaging radiation exposure following breast-conservation therapy. Annals of Surgical Oncology. 18: 104-8. PMID 20717730 DOI: 10.1245/S10434-010-1279-6 |
0.382 |
|
| 2011 |
Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 295-300. PMID 20657034 DOI: 10.1093/Annonc/Mdq342 |
0.338 |
|
| 2011 |
Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Morrow M, Gemignani ML. Determinants of outcome in elderly patients with positive sentinel lymph nodes. American Journal of Surgery. 201: 734-40. PMID 20619395 DOI: 10.1016/J.Amjsurg.2010.02.005 |
0.408 |
|
| 2011 |
Perez C, Gupta G, King T, Rogers K, McLane A, Patil S, Traina T, Robson M, McCormick B, Ho A. Black Race is Associated with Higher Risk of Locoregional Recurrence after Breast-conserving Therapy in Patients with Triple Negative Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 81: S204. DOI: 10.1016/J.Ijrobp.2011.06.370 |
0.355 |
|
| 2010 |
Drullinsky P, Sugarman SM, Fornier MN, D'Andrea G, Gilewski T, Lake D, Traina T, Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, ... Patil S, et al. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clinical Breast Cancer. 10: 440-4. PMID 21147686 DOI: 10.3816/Cbc.2010.N.057 |
0.435 |
|
| 2010 |
Arora N, King TA, Jacks LM, Stempel MM, Patil S, Morris E, Morrow M. Impact of breast density on the presenting features of malignancy. Annals of Surgical Oncology. 17: 211-8. PMID 20853035 DOI: 10.1245/S10434-010-1237-3 |
0.4 |
|
| 2010 |
Pugliese M, Stempel M, Patil S, Hsu M, Ho A, Traina T, Morrow M, Cody H, Gemignani ML. The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. American Journal of Surgery. 200: 368-73. PMID 20800716 DOI: 10.1016/J.Amjsurg.2009.10.016 |
0.432 |
|
| 2010 |
Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3762-9. PMID 20625132 DOI: 10.1200/Jco.2009.26.8847 |
0.424 |
|
| 2010 |
Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, Dickler M, Hudis CA, Jochelson M, McArthur HL. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3154-9. PMID 20516453 DOI: 10.1200/Jco.2009.27.5743 |
0.343 |
|
| 2010 |
Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2982-8. PMID 20479410 DOI: 10.1200/Jco.2009.26.5900 |
0.391 |
|
| 2010 |
Rudloff U, Brogi E, Reiner AS, Goldberg JI, Brockway JP, Wynveen CA, McCormick B, Patil S, Van Zee KJ. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Annals of Surgery. 251: 583-91. PMID 20224381 DOI: 10.1097/Sla.0B013E3181B5931E |
0.397 |
|
| 2010 |
Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1706-13. PMID 20194867 DOI: 10.1200/Jco.2009.25.1561 |
0.375 |
|
| 2010 |
Port ER, Patil S, Stempel M, Morrow M, Cody HS. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment? Cancer. 116: 1987-91. PMID 20151427 DOI: 10.1002/Cncr.24964 |
0.323 |
|
| 2010 |
Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 116: 347-54. PMID 19921736 DOI: 10.1002/Cncr.24713 |
0.373 |
|
| 2010 |
Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 628-33. PMID 19841327 DOI: 10.1200/Jco.2009.21.8784 |
0.48 |
|
| 2010 |
Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investigational New Drugs. 28: 523-8. PMID 19547919 DOI: 10.1007/S10637-009-9280-2 |
0.352 |
|
| 2010 |
Patil S, Figlin RA, Hutson TE, Michaelson D, Negrier S, Kim ST, Huang X, Motzer RJ. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology. 28: 4594-4594. DOI: 10.1200/Jco.2010.28.15_Suppl.4594 |
0.327 |
|
| 2010 |
Kiess A, McArthur H, Mahoney K, Patil S, Morris P, Ho A, Hudis C, McCormick B. Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women who Undergo Breast Conservation Therapy for Node-Negative HER2-Positive Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 78: S98. DOI: 10.1016/j.ijrobp.2010.07.257 |
0.336 |
|
| 2009 |
Wiechmann L, Jacks L, Patil S, Stempel M, Morrow M. Impact of molecular subtype on presenting characteristics of T1a,b tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11111. PMID 27963488 DOI: 10.1200/Jco.2009.27.15_Suppl.11111 |
0.379 |
|
| 2009 |
Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5042. PMID 27962940 DOI: 10.1200/Jco.2009.27.15_Suppl.5042 |
0.335 |
|
| 2009 |
Blinder VS, Patil S, Diamant A, Thind A, Maly R. Employment status among low-income Caucasian and Latina breast cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6612. PMID 27961765 DOI: 10.1200/Jco.2009.27.15_Suppl.6612 |
0.42 |
|
| 2009 |
Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. PIK3CA Mutation Associates with Improved Outcome in Breast Cancer Clinical Cancer Research. 15: 5049-5059. PMID 19671852 DOI: 10.1158/1078-0432.Ccr-09-0632 |
0.417 |
|
| 2009 |
Hurria A, Li D, Hansen K, Patil S, Gupta R, Nelson C, Lichtman SM, Tew WP, Hamlin P, Zuckerman E, Gardes J, Limaye S, Lachs M, Kelly E. Distress in older patients with cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4346-51. PMID 19652074 DOI: 10.1200/Jco.2008.19.9463 |
0.347 |
|
| 2009 |
Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3379-84. PMID 19487380 DOI: 10.1200/Jco.2008.20.9817 |
0.374 |
|
| 2009 |
Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Port ER, Morrow M, Gemignani ML. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. Annals of Surgical Oncology. 16: 1952-8. PMID 19381724 DOI: 10.1245/S10434-009-0440-6 |
0.31 |
|
| 2009 |
Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1432-9. PMID 19224847 DOI: 10.1200/Jco.2008.19.0108 |
0.32 |
|
| 2009 |
Rudloff U, Brogi E, Brockway JP, Goldberg JI, Cranor M, Wynveen CA, Nehhozina T, Reiner AS, Patil S, Van Zee KJ. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 115: 1203-14. PMID 19170233 DOI: 10.1002/Cncr.24166 |
0.464 |
|
| 2009 |
Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Research and Treatment. 117: 205-210. PMID 18622739 DOI: 10.1007/S10549-008-0116-0 |
0.424 |
|
| 2008 |
Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L. Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients? Annals of Surgical Oncology. 15: 2728-33. PMID 18688679 DOI: 10.1245/S10434-008-0050-8 |
0.371 |
|
| 2008 |
Jathavedam A, Feldman DR, Ishill N, Turkula S, Patil S, Bosl GJ, Motzer RJ, Weinstock DM. Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 595-600. PMID 18410903 DOI: 10.1016/J.Bbmt.2008.02.020 |
0.338 |
|
| 2008 |
Traina TA, Theodoulou M, Feigin K, Patil S, Tan KL, Edwards C, Dugan U, Norton L, Hudis C. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1797-802. PMID 18398145 DOI: 10.1200/Jco.2007.13.8388 |
0.438 |
|
| 2007 |
Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors Clinical Cancer Research. 13: 5841-5846. PMID 17908977 DOI: 10.1158/1078-0432.Ccr-07-1218 |
0.359 |
|
| 2007 |
Hurria A, Lichtman SM, Gardes J, Li D, Limaye S, Patil S, Zuckerman E, Tew W, Hamlin P, Abou‐Alfa GK, Lachs M, Kelly E. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. Journal of the American Geriatrics Society. 55: 1604-1608. PMID 17697101 DOI: 10.1111/J.1532-5415.2007.01367.X |
0.343 |
|
| 2007 |
Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S, Van Zee KJ. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Annals of Surgical Oncology. 14: 2961-70. PMID 17562113 DOI: 10.1245/S10434-007-9439-Z |
0.394 |
|
| 2007 |
Feldman DR, Kondagunta GV, Ginsberg MS, Ishill N, Patil S, Cestaro J, Obbens E, Sheinfeld J, Bosl GJ, Motzer RJ. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Investigational New Drugs. 25: 487-90. PMID 17520176 DOI: 10.1007/S10637-007-9059-2 |
0.368 |
|
| 2007 |
Feldman DR, Kondagunta GV, Ronnen EA, Fischer P, Chang R, Baum M, Ginsberg MS, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology. 25: 5099-5099. DOI: 10.1200/Jco.2007.25.18_Suppl.5099 |
0.303 |
|
| 2006 |
Patil SM, Shope JT, Raghunathan TE, Bingham CR. The role of personality characteristics in young adult driving. Traffic Injury Prevention. 7: 328-34. PMID 17114089 DOI: 10.1080/15389580600798763 |
0.463 |
|
| 2003 |
Shope JT, Raghunathan TE, Patil SM. Examining trajectories of adolescent risk factors as predictors of subsequent high-risk driving behavior. The Journal of Adolescent Health : Official Publication of the Society For Adolescent Medicine. 32: 214-24. PMID 12606115 DOI: 10.1016/S1054-139X(02)00424-X |
0.451 |
|
| 2001 |
Shope JT, Waller PF, Raghunathan TE, Patil SM. Adolescent antecedents of high-risk driving behavior into young adulthood: substance use and parental influences. Accident; Analysis and Prevention. 33: 649-58. PMID 11491245 DOI: 10.1016/S0001-4575(00)00079-8 |
0.458 |
|
| Show low-probability matches. |